Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2006-2009

ABSTRACT

This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Avastin will be given as first-line treatment in combination with platinum-based chemotherapy or in combination with any standard of care NSCLC first-line chemotherapy used in line with the licensed national prescribing information. Eligible patients will receive Avastin (15mg/kg iv on day 1 of each 3 week cycle) concomitantly with chemotherapy. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 500+ individuals. More... »

URL

https://clinicaltrials.gov/show/NCT00451906

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Avastin will be given as first-line treatment in combination with platinum-based chemotherapy or in combination with any standard of care NSCLC first-line chemotherapy used in line with the licensed national prescribing information. Eligible patients will receive Avastin (15mg/kg iv on day 1 of each 3 week cycle) concomitantly with chemotherapy. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 500+ individuals.", 
    "endDate": "2009-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00451906", 
    "keywords": [
      "open-label study", 
      "platinum", 
      "first-line treatment", 
      "patient", 
      "non small cell lung cancer", 
      "single-arm", 
      "safety", 
      "efficacy", 
      "Avastin", 
      "chemotherapy regimen", 
      "Non-Small-Cell Lung Carcinoma", 
      "platinum-based chemotherapy", 
      "prescribing", 
      "eligible patient", 
      "IVS", 
      "cycle", 
      "Drug Therapy", 
      "completion", 
      "disease progression", 
      "target sample size", 
      "individual"
    ], 
    "name": "Open-label Study of Bevacizumab (AVASTIN\u00ae) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00451906"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00003.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.418158.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2006-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s40261-012-0001-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020175306", 
          "https://doi.org/10.1007/s40261-012-0001-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70151-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041715118"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00451906"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00451906'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00451906'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00451906'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00451906'


 

This table displays all metadata directly associated to this object as RDF triples.

47 TRIPLES      16 PREDICATES      38 URIs      30 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00451906 schema:about anzsrc-for:3142
2 schema:description This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Avastin will be given as first-line treatment in combination with platinum-based chemotherapy or in combination with any standard of care NSCLC first-line chemotherapy used in line with the licensed national prescribing information. Eligible patients will receive Avastin (15mg/kg iv on day 1 of each 3 week cycle) concomitantly with chemotherapy. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 500+ individuals.
3 schema:endDate 2009-06-01T00:00:00Z
4 schema:keywords Avastin
5 Drug Therapy
6 IVS
7 Non-Small-Cell Lung Carcinoma
8 chemotherapy regimen
9 completion
10 cycle
11 disease progression
12 efficacy
13 eligible patient
14 first-line treatment
15 individual
16 non small cell lung cancer
17 open-label study
18 patient
19 platinum
20 platinum-based chemotherapy
21 prescribing
22 safety
23 single-arm
24 target sample size
25 schema:name Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer
26 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00451906
27 schema:sdDatePublished 2019-03-07T15:22
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher N0d1a12c55c484a90aace4f8ef6cc11a2
30 schema:sponsor https://www.grid.ac/institutes/grid.418158.1
31 schema:startDate 2006-08-01T00:00:00Z
32 schema:subjectOf sg:pub.10.1007/s40261-012-0001-9
33 https://doi.org/10.1016/s1470-2045(10)70151-0
34 schema:url https://clinicaltrials.gov/show/NCT00451906
35 sgo:license sg:explorer/license/
36 sgo:sdDataset clinical_trials
37 rdf:type schema:MedicalStudy
38 N0d1a12c55c484a90aace4f8ef6cc11a2 schema:name Springer Nature - SN SciGraph project
39 rdf:type schema:Organization
40 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
41 rdf:type schema:DefinedTerm
42 sg:pub.10.1007/s40261-012-0001-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020175306
43 https://doi.org/10.1007/s40261-012-0001-9
44 rdf:type schema:CreativeWork
45 https://doi.org/10.1016/s1470-2045(10)70151-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041715118
46 rdf:type schema:CreativeWork
47 https://www.grid.ac/institutes/grid.418158.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...